Perspective Therapeutics (CATX) Other financing activities (2012 - 2023)
Perspective Therapeutics' (CATX) quarterly Other financing activities came in at $65000.0 in Q1 2023, up 1146.17% quarter-over-quarter from $5216.0 in Q1 2012.
Perspective Therapeutics (CATX) Other financing activities (2012 - 2023) Analysis & Trends
Perspective Therapeutics has disclosed Other financing activities across 2 years of filings, most recently posting $65000.0 for Q1 2023.
- Other financing activities for Q1 2023 came in at $65000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $65000.0 (up 1146.17% YoY), and the FY2023 annual result was $65000.0, changed N/A from the prior year.
- Other financing activities came in at $65000.0 for Q1 2023 at Perspective Therapeutics, up from $5216.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $65000.0 in Q1 2023 to a low of $65000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Perspective Therapeutics | 308.74 Mn | 308.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 65,000.00 |
| Mar 31, 2023 | 65,000.00 |
| Mar 31, 2012 | 5,216.00 |
| Mar 31, 2012 | 5,216.00 |